- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib, Dexamethasone, Prednisone, Methylprednisolone, Lenalidomide, Pomalidomide
- Drug
- Lead sponsor
- Oncotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 7
- States / cities
- Encinitas, California • West Hills, California • West Hollywood, California + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Multiple Myeloma
- Interventions
- Zoledronic Acid
- Drug
- Lead sponsor
- Hoosier Cancer Research Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 8
- States / cities
- Elkhart, Indiana • Evansville, Indiana • Indianapolis, Indiana + 3 more
- Conditions
- Hematological Malignancy, Leukemia, Lymphoid Leukemia, Multiple Myeloma, Myeloid Leukemia, Monocytic Leukemia, Non-hodgkin Lymphoma, Other Hematologic Condition
- Interventions
- Behavioral Coaching Intervention, Virtual Exercise Platform
- Behavioral
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- N-803
- Biological
- Lead sponsor
- Altor BioScience
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 4
- States / cities
- Minneapolis, Minnesota • St Louis, Missouri • Buffalo, New York + 1 more
- Conditions
- Hematologic Malignancy, Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Mantle Cell Lymphoma, Multiple Myeloma, Diffuse Large B Cell Lymphoma
- Interventions
- autologous hematopoietic stem cells added to planned CAR T
- Biological
- Lead sponsor
- Joshua Sasine, MD, PhD
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- High-risk Smoldering Multiple Myeloma
- Interventions
- Siltuximab, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Rockville, Maryland • Detroit, Michigan + 5 more
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Multiple Myeloma
- Interventions
- everolimus, bendamustine hydrochloride
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Interventions
- dalteparin, lenalidomide, dexamethasone, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Chronic Myeloproliferative Disorders, Fanconi Anemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- microarray analysis, polyacrylamide gel electrophoresis, polymerase chain reaction, protein expression analysis, reverse transcriptase-polymerase chain reaction, western blotting, chromatography, high performance liquid chromatography, immunoenzyme technique
- Genetic · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 1 Year to 55 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1975 – 2016
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Multiple Myeloma
- Interventions
- MGTA-145, Plerixafor
- Drug
- Lead sponsor
- Surbhi Sidana, MD
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Leukemia, Multiple Myeloma
- Interventions
- CIK cells, etoposide, bcnu, cyclophosphamide, gemcitabine, vinorelbine, melphalan
- Drug
- Lead sponsor
- Sally Arai
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Multiple Myeloma
- Interventions
- Panobinostat Capsules, Bortezomib Injection, Dexamethasone tablets
- Drug
- Lead sponsor
- pharmaand GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 9
- States / cities
- Fayetteville, Arkansas • Los Angeles, California • Fort Collins, Colorado + 6 more
- Conditions
- Multiple Myeloma
- Interventions
- Sotatercept, Placebo
- Drug
- Lead sponsor
- Rebecca Silbermann
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Iberdomide, Belantamab Mafodotin, Dexamethasone, Echocardiography, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection
- Drug · Biological · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 40
- States / cities
- Ames, Iowa • Boone, Iowa • Fort Dodge, Iowa + 27 more
- Conditions
- Multiple Myeloma, Renal Insufficiency
- Interventions
- Carfilzomib
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 5
- States / cities
- San Francisco, California • Baltimore, Maryland • Detroit, Michigan + 2 more
- Conditions
- Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- anti-thymocyte globulin, donor lymphocytes, filgrastim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, reduced-intensity transplant conditioning procedure, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Other + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- Up to 69 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 10
- States / cities
- Lewes, Delaware • Newark, Delaware • Orlando, Florida + 7 more
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
- Interventions
- Plant based meals
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Cancer
- Interventions
- DNA analysis, polymorphism analysis, laboratory biomarker analysis, medical chart review, questionnaire administration, assessment of therapy complications, evaluation of cancer risk factors
- Genetic · Other · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Cancer
- Interventions
- recombinant interferon alfa-2b, sodium stibogluconate, SSG & interferon
- Biological · Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Plasma Cell Leukemia, Plasma Cell Myeloma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Elotuzumab, Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Natural Killer Cell Therapy, Umbilical Cord Blood-Derived Lymphocyte Therapy
- Procedure · Biological · Other + 1 more
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma, Myeloma, Smoldering Multiple Myeloma
- Interventions
- (Anti-KIR)
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- ALLO-605, ALLO-647, Fludarabine, Cyclophosphamide
- Genetic · Biological · Drug
- Lead sponsor
- Allogene Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Austin, Texas • Houston, Texas + 1 more
- Conditions
- Plasma Cell Myeloma
- Interventions
- Bortezomib, Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,087 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2034
- U.S. locations
- 909
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Hot Springs, Arkansas + 551 more
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Interventions
- alvocidib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota